【ST惠程：控股子公司受让奥利司他胶囊药品批准文号获批】ST惠程公告称，公司控股子公司锐恩医药以702.78万元受让星创医药持有的奥利司他胶囊药品注册批件、药品上市许可持有人权利及相关技术资料与知识产权。近日锐恩医药收到国家药监局核准签发的《药品补充申请批准通知书》，该药品上市许可持有人已变更为锐恩医药，药品批准文号不变，生产场地、处方等均无变更，通过GMP符合性检查且符合放行要求后可上市销售。该事项对公司未来业绩的影响存在不确定性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.